/GLPG
GLPG Stock - Galapagos N.V.
Healthcare|BiotechnologyNASDAQ
$32.36+2.31%
+$0.73 (+2.31%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.64
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).60
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+5.1%upside
Target: $34.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GLPG
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$32.04 – $32.68
TARGET (TP)$34.00
STOP LOSS$29.77
RISK/REWARD1:0.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.05
52W High$37.78
52W Low$22.36
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $275.65M | $239.72M | $241.25M | $484.85M | $478.05M |
| Gross Profit | $240.79M | $239.72M | $241.25M | $483.22M | $-45,614,000 |
| Gross Margin | 87.4% | 100.0% | 100.0% | 99.7% | -9.5% |
| Operating Income | $-188,338,000 | $-88,263,000 | $-131,056,000 | $-165,597,000 | $-178,632,000 |
| Net Income | $74.08M | $211.70M | $-217,991,000 | $-125,422,000 | $-305,436,000 |
| Net Margin | 26.9% | 88.3% | -90.4% | -25.9% | -63.9% |
| EPS | $1.12 | $-0.06 | $-3.32 | $-1.91 | $-4.78 |
Company Overview
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
25%
Hold / Neutral
4
50%
Sell / Underperform
2
25%
Analyst Consensus🔴 Bearish
2 Bullish6 Neutral/Bearish
Price Targets
$38
Average Target
↑ 16.2% Upside
Now
$22
Low
$38
Average
$61
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 22nd 2025 | Leerink Partners | Upgrade | Outperform | $40 |
| August 5th 2025 | Deutsche Bank | Downgrade | Sell | - |
| February 14th 2025 | Morgan Stanley | Downgrade | Underweight | $22← $31 |
| November 20th 2024 | Kepler | Downgrade | Reduce | - |
| September 9th 2024 | Leerink Partners | Initiation | Market Perform | $24 |
| August 2nd 2024 | Raymond James | Downgrade | Market Perform | - |
| March 28th 2024 | BofA Securities | Downgrade | Underperform | $31← $41 |
| March 7th 2024 | Morgan Stanley | Resumed | Equal Weight | $38 |
| August 24th 2023 | Citigroup | Downgrade | Neutral | - |
| May 5th 2023 | Raymond James | Upgrade | Outperform | - |
| January 23rd 2023 | Jefferies | Upgrade | Hold | $47.2← $49 |
| November 7th 2022 | Raymond James | Downgrade | Market Perform | - |
| September 9th 2022 | Morgan Stanley | Downgrade | Equal Weight | $61← $80 |
Earnings History & Surprises
GLPGBeat Rate
74%
Last 19 quarters
Avg Surprise
-34.5%
EPS vs Estimate
Beats / Misses
14/5
Last 12 quarters
Latest EPS
$-3.59
Q4 2025
EPS Surprise History
Q1 24
+302.5%
$2.39vs$-1.18
Q2 24
+425.0%
$0.39vs$-0.12
Q3 24
+450.1%
$0.14vs$0.03
Q4 24
-185.2%
$-0.77vs$-0.27
Q1 25
+263.3%
$0.39vs$-0.24
Q2 25
-973.9%
$-2.47vs$-0.23
Q3 25
-182.3%
$-1.89vs$-0.67
Q4 25
-1696.4%
$-3.59vs$-0.20
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 23, 2026 | $1.32 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.20 | $-3.59 | -1696.4% | ✗ MISS |
Q3 2025 | Jul 23, 2025 | $-0.67 | $-1.89 | -182.3% | ✗ MISS |
Q2 2025 | Apr 23, 2025 | $-0.23 | $-2.47 | -973.9% | ✗ MISS |
Q1 2025 | Feb 28, 2025 | $-0.24 | $0.39 | +263.3% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $-0.27 | $-0.77 | -185.2% | ✗ MISS |
Q3 2024 | Sep 12, 2024 | $0.03 | $0.14 | +450.1% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.12 | $0.39 | +425.0% | ✓ BEAT |
Q1 2024 | Feb 23, 2024 | $-1.18 | $2.39 | +302.5% | ✓ BEAT |
Q4 2023 | Nov 3, 2023 | $-0.62 | $0.39 | +162.9% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.70 | $0.08 | +111.4% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.87 | $0.43 | +149.4% | ✓ BEAT |
Q1 2023 | Feb 24, 2023 | $-1.90 | $-1.99 | -4.7% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-1.05 | $0.33 | +131.4% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.66 | $-0.29 | +56.1% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.77 | $-0.20 | +74.0% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-1.12 | $0.25 | +122.3% | ✓ BEAT |
Q4 2021 | Nov 5, 2021 | $-1.67 | $-1.17 | +29.9% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-1.27 | $-0.98 | +22.8% | ✓ BEAT |
Q2 2021 | May 6, 2021 | $-1.71 | $-0.24 | +86.0% | ✓ BEAT |
Latest News
Galapagos' GLPG3667 Meets Primary Endpoint In Dermatomyositis Study, Shows Mixed Results In Lupus Phase 3-Enabling Trials; Galapagos Will Evaluate All Strategic Alternatives, Including Resumption Of Its Partnering Process, To Accelerate Further Development Of GLPG3667 In Dermatomyositis And Potentially Other Severe Auto-Immune Indications
➖ NeutralBenzinga•Dec 18, 2025, 09:02 PM
Galapagos Shares Updated ATALANTA-1 Results At ASH 2025 Showing High Response Rates And Durable Responses With GLPG5101 In MCL
📈 PositiveBenzinga•Dec 8, 2025, 07:42 AM
RBC Capital Maintains Sector Perform on Galapagos, Raises Price Target to $32
➖ NeutralBenzinga•Nov 7, 2025, 07:04 PM
Galapagos NV To Present New In Vitro Pharmacological Data On Its Selective TYK2 Inhibitor, GLPG3667 At ACR Convergence 2025 Conference In Chicago From October 24–29, 2025
📈 PositiveBenzinga•Oct 23, 2025, 08:10 PM
RBC Capital Maintains Sector Perform on Galapagos, Raises Price Target to $28
➖ NeutralBenzinga•Oct 22, 2025, 02:17 PM
Leerink Partners Upgrades Galapagos to Outperform, Raises Price Target to $40
📈 PositiveBenzinga•Oct 21, 2025, 08:43 PM
Galapagos shares are trading lower after the company announced plans to wind down its cell therapy business and redirect cash toward transformational deals.
📉 NegativeBenzinga•Oct 21, 2025, 11:51 AM
Galapagos falls after plans to shut down cell therapy unit
📉 NegativeSeeking Alpha•Oct 21, 2025, 11:40 AM
Galapagos Plans To Wind Down Cell Therapy Business And Redirect Cash Toward Transformational Deals
📈 PositiveBenzinga•Oct 21, 2025, 06:00 AM
Galapagos Says As Of Today's Date, The Board Has Received A Limited Number Of Non-binding Offers From Consortia, Predominantly Comprised Of Financial Investors, To Acquire The Cell Therapy Business.
➖ NeutralBenzinga•Oct 1, 2025, 08:03 PM
Galapagos NV Advances Cell Therapy Business Divestment Review; Expects Decision By November 5, 2025
➖ NeutralBenzinga•Oct 1, 2025, 08:02 PM
Frequently Asked Questions about GLPG
What is GLPG's current stock price?
Galapagos N.V. (GLPG) is currently trading at $32.36 per share. The stock has moved +2.31% today.
What is the analyst price target for GLPG?
The average analyst price target for GLPG is $34.00, based on 1 analyst.
What sector is Galapagos N.V. in?
Galapagos N.V. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GLPG's market cap?
Galapagos N.V. has a market capitalization of $2.13 billion, making it a mid-cap company.
Does GLPG pay dividends?
No, Galapagos N.V. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCOGT
Cogent Biosciences, Inc.
$39.55
Mkt Cap: $5.6B
DNLI
Denali Therapeutics Inc.
$16.85
Mkt Cap: $2.5B
ETNB
89bio, Inc.
$14.84
Mkt Cap: $2.2B
GPCR
Structure Therapeutics Inc.
$64.94
Mkt Cap: $3.7B
IBRX
ImmunityBio, Inc.
$2.08
Mkt Cap: $2.0B
MESO
Mesoblast Limited
$19.48
Mkt Cap: $2.5B
OCUL
Ocular Therapeutix, Inc.
$12.56
Mkt Cap: $2.2B
QURE
uniQure N.V.
$23.99
Mkt Cap: $1.3B
RCUS
Arcus Biosciences, Inc.
$21.98
Mkt Cap: $2.4B
VRDN
Viridian Therapeutics, Inc.
$31.92
Mkt Cap: $2.6B
Explore stocks similar to GLPG for comparison